Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet receptors.

R W Colman1

  • 1Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania.

Hematology/Oncology Clinics of North America
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Researchers identified key platelet receptors like ADP, collagen, and thrombin. Understanding these receptors and their activation pathways can lead to more targeted drug therapies for platelet-related conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).

Thrombosis and haemostasis·2011
Same author

Platelet cAMP and cGMP Phosphodiesterases.

Platelets·2010
Same author

Platelet-kininogen Interactions.

Platelets·2010
Same author

Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.

Oncogene·2009
Same author

Domain 5 of kininogen inhibits proliferation of human colon cancer cell line (HCT-116) by interfering with G1/S in the cell cycle.

Journal of thrombosis and haemostasis : JTH·2006
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Platelet biochemistry
  • Molecular biology of cell receptors
  • Hematology

Background:

  • Platelet receptors are crucial for hemostasis and thrombosis.
  • Advances in molecular biology have enabled detailed characterization of these receptors.
  • Understanding receptor function is key to developing targeted therapies.

Purpose of the Study:

  • To review the current understanding of platelet receptor biochemistry and function.
  • To highlight the identification and characterization of key platelet receptors.
  • To explore the implications for developing specific anti-platelet drugs.

Main Methods:

  • Affinity labeling (FSBA) for ADP receptor identification.
  • Receptor antagonists and photoaffinity labels for thromboxane A2 receptor.

Related Experiment Videos

  • Cloning and expression of alpha 2-adrenergic receptor.
  • Identification of GP Ib as the thrombin receptor.

    • Main Results:

    • Aggregin identified as the ADP receptor, mediating shape change and aggregation.
    • GP Ia and GP IV are key collagen receptors.
    • Thromboxane A2 receptor characterized.
    • Alpha 2-adrenergic receptor cloned and expressed.
    • Thrombin receptor (GP Ib) activation leads to aggregin cleavage and GP IIb/IIIa exposure, causing aggregation.

    Conclusions:

    • Isolation and expression of ADP, collagen, and thrombin receptors offer new therapeutic targets.
    • A deeper understanding of platelet stimulus-response coupling will enhance drug specificity.
    • Targeting specific platelet receptors can lead to more effective and selective treatments for thrombotic disorders.